AbbVie wins FDA approval for Juvmo. AbbVie stock sits 3.48 percent below its 52-week high
Published on 10/02/2026 at 14:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. (ISIN US00287Y1091) won U.S. FDA approval for Juvmo on September 28, 2026, while AbbVie stock sat 3.48 percent below its 52-week high of USD 269.39. The company said the once-daily Parkinson's disease treatment should become available in the United States in October 2026, according to AbbVie.
Juvmo adds a new growth asset
Juvmo is the first selective D1/D5 receptor agonist approved for adults with Parkinson's disease, according to the September 28 release. The approval moves a late-stage neuroscience asset into commercialization and expands AbbVie's portfolio beyond immunology, oncology and aesthetics.
Reuters reported on September 25, 2026, that the FDA approval covered tavapadon, which AbbVie obtained through its USD 8.70 billion Cerevel Therapeutics acquisition. Reuters also reported that Citi analysts expected gradual uptake as Medicare coverage negotiations progressed.
Revenue growth supports the pipeline
AbbVie reported adjusted earnings per share of USD 3.65 and revenue of USD 16.99 billion in the second quarter of 2026, with revenue up 10.20 percent year over year, according to MarketBeat. The same report said the company guided to adjusted earnings per share of USD 3.84-3.88 for the third quarter of 2026.
MarketBeat listed 23 buy ratings, two strong-buy ratings and six hold ratings among 31 brokerages, with an average one-year target of USD 272.66 on September 29, 2026. That target stood USD 12.63 above the primary-exchange price of USD 260.03, while the 52-week range ran from USD 190.75 to USD 269.39.
Stock price holds near the yearly high
AbbVie had a market capitalization of USD 459.4 billion as of October 1, 2026. Its primary exchange is the NYSE, where the stock was last quoted at USD 260.03 at 4:00 p.m. ET on October 1, 2026; that quote was 3.48 percent below the 52-week high.
AbbVie stock was trading at EUR 231.50 at Lang & Schwarz on October 2, 2026 at 2:37 p.m. CEST, down 0.09 percent versus the prior close of EUR 231.70. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.
AbbVie stock at a glance
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 2, 2026, 2:37 p.m. CEST): EUR 231.50
- Change versus prior close: minus 0.09 percent
- Prior close Lang & Schwarz (October 1, 2026): EUR 231.70
- Market capitalization: USD 459.4 billion (as of October 1, 2026)
- 52-week range: USD 190.75-269.39 (as of October 1, 2026)
- Sector / Industry: Health care / Pharmaceuticals
